Methods and pharmacological compositions for wound healing

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine and may be used to heal wound epithelium of various genesis. For this purpose an agent is introduced into wound, causing modulation of expression and/or activity of one isoform PKC and therapeutically effective amount of one additional facility selected from group that consists of insulin, growth factor, adipokin, PKC RACK and GW9662. According pharmaceutical compositions are proposed for introduction in wound, containing, apart from therapeutically effective amounts of necessary substances, a pharmaceutically acceptable carrier.

EFFECT: accelerated processes of epithelium wound healing by explicit synergetic action of specified substances.

60 cl, 43 dwg, 10 tbl, 27 ex

 

The text descriptions are given in facsimile form.

1. Method of induction of wound-healing process of the epithelium, including the introduction to the wound a therapeutically effective amount of insulin and at least one additional means having a synergistic action with the specified insulin, for the induction of wound-healing process of the epithelium.

2. The method according to claim 1, where the specified insulin is recombinant or has a natural origin.

3. The method according to claim 1, where the specified therapeutically effective amount of insulin includes the insulin concentration in the range from 0.1 to 10 microns.

4. The method according to claim 1, where the aforementioned at least one additional agent is an inhibitor α, growth factor or δ RACK.

5. The method according to claim 4, where the specified additional agent is an inhibitor α.

6. The method according to claim 4, where the specified additional agent is an inhibitor RKS N-monitorowania peptide pseudoobscura α.

7. The method according to claim 4, where the specified growth factor is a PDG, EGF, TGFβ, KGF, ECGF and IGF1.

8. The method according to any one of claims 1 to 7, where this wound epithelium selected from the group consisting of ulcers, wounds associated with diabetes, burns, sunburn, chronic skin wounds, lacerated wounds of the cornea, wound inflammatory disease of the gastrointestinal tract, wounds, inflammatory bowel disease, wounds in Crohn's disease, ulcerative colitis, hemorrhoids, wounds in epidermolysis-bullosa, a skin-naravnoy wound, a psoriasis wound, wounds of the skin of the animal, diabetic animal wounds, wounds with retinopathy, wounds in the mouth (mucositis), wounds of the vaginal mucosa, wounds when gum disease, lacerations, wounds, surgical incisions and postoperative adhesive wound.

9. The method of claim 8, where this plague is selected from the group consisting of diabetic ulcers, decubitus ulcer, venous ulcer, gastric ulcers and ulcers associated with HIV.

10. The method according to any one of claims 1 to 7, where specified insulin and at least one additional funds are contained in the pharmaceutical composition, adapted for local use.

11. The method according to claim 10, where the specified pharmaceutical composition selected from the group consisting of an aqueous solution, gel, cream, paste, lotion, spray, suspension, powder, colloidal solution, balm and ointments.

12. The method according to claim 11, where the specified pharmaceutical compositionlocal a solid Foundation.

13. Method of induction of wound-healing process of the epithelium, including the modulation of expression and/or activity of at least one isoform of the RCC in colonizing the area of the wound epithelium dermal cells and introduction to these dermal cells therapeutically effective amount of at least one additional means selected from the group consisting of insulin, growth factor, adipokine, RKS RACK and GW9662 in order to thereby accelerate the healing process of the wound epithelium.

14. The method according to item 13, where these dermal cells are fibroblasts or keratinocytes.

15. The method according to 14, where this isoform RKS selected from the group consisting of α, β, δ, ε, η and ζ.

16. The method according to 14, where the specified growth factor selected from the group consisting of IL-6, KGF, and TNFα, as specified adipokine is adipsin or adiponectin.

17. The method according to item 13, where the expression and/or activity specified isoforms RKS ingibirovany.

18. The method according to 17, where the inhibition of this isoform CSWs reached by means of small molecules interfering RNA (siRNA) or by infection of these dermal cells adenoviral design with dominant-negative CSWs.

19. The method according to item 13, where the expression and/or activity specified isoforms RRT is activated.

20. The method according to claim 19, where the asset is AI specified isoforms CSWs reached by infection of these dermal cells adenoviral construct with isoform RKS wild-type.

21. The method according to p, where this isoform RKS is a α, and this additional tool is insulin, TNFα, adipsin or δ RACK.

22. The method according to p, where this isoform RKS is a β, and this additional tool is insulin, KGF, IL-6 or GW9662.

23. The method according to p, where this isoform RKS is a ζ, and this additional tool is insulin, IL-6, TNFα, KGF or adiponectin.

24. The method according to claim 20, where this isoform RKS is a δ, and said additional means is adipsin.

25. The method according to item 13, including the introduction of these dermal cells therapeutically effective amounts of substances capable of modulating the expression and/or activity of at least one specified isoforms of the RCC and the specified additional funds.

26. The method according A.25, where the specified substance is an inhibitor α, preferably N-monitorowania peptide pseudoobscura α.

27. The method according to p, where this additional tool is insulin.

28. The method according to item 27, including the introduction of these dermal cells therapeutically effective amounts of N-monitorowania peptide pseudoobscura α and insulin.

29. The method according A.25, where MC is related substance is an inhibitor β; inhibitor η, preferably N-monitorowania peptide pseudoobscura η or inhibitor ζ, preferably N-monitorowania peptide pseudoobscura ζ.

30. The method according A.25, where the specified substance is an activator δ, preferably insulin or δ RACK.

31. The method according to any of PP-30, where this wound epithelium selected from the group consisting of ulcers, wounds associated with diabetes, burns, sunburn, chronic skin wounds, lacerated wounds of the cornea, wound inflammatory disease of the gastrointestinal tract, wounds, inflammatory bowel disease, wounds in Crohn's disease, ulcerative colitis, hemorrhoids, wounds in epidermolysis-bullosa, a skin-naravnoy wound, a psoriasis wound, wounds of the skin of the animal, diabetic animal wounds, wounds with retinopathy, wounds in the mouth (mucositis), wounds of the vaginal mucosa, wounds when gum disease, lacerations, wounds, surgical incisions and postoperative adhesive wound.

32. The method according to p, where this plague is selected from the group consisting of diabetic ulcers, decubitus ulcer, venous ulcer, gastric ulcers and ulcers associated with HIV.

33. The method according to any of PP-30, where the specified substance and additional means are contained in a pharmaceutical carrier adapted for topical application.

34. The method according to p, where is shown a pharmaceutical composition selected from the group consisting of an aqueous solution, gel, cream, paste, lotion, spray, suspension, powder, colloidal solution, balm and ointments.
35 the Method according to clause 34, where this pharmaceutical composition includes a solid Foundation.

36. Pharmaceutical composition for topical use for the induction of wound-healing process of epithelium, containing a therapeutically effective amount of insulin and at least one additional tool that has a synergistic effect with the specified insulin, and a pharmaceutically acceptable carrier.

37. The pharmaceutical composition according p, where specified, the insulin is recombinant or has a natural origin.

38. The pharmaceutical composition according p, where the specified therapeutically effective amount of insulin includes the insulin concentration in the range from 0.1 to 10 microns.

39. The pharmaceutical composition according p, where the aforementioned at least one additional agent is an inhibitor α, growth factor or δ RACK.

40. The pharmaceutical composition according to § 39, where this additional tool is an inhibitor α.

41. The pharmaceutical composition according to § 39, where this additional tool is an inhibitor α N-monitorowania peptide pseudoobscura α.

42. Pharmaceutical to notice in § 39, where the specified growth factor is a PDGF, EGF, TGFβ, KGF, ECGF and IGF1.

43. Pharmaceutical composition for topical use for the induction of wound-healing process of epithelium, containing a therapeutically effective amount of a substance capable of modulating the expression and/or activity of at least one isoform of the RCC and at least one additional agent selected from the group consisting of insulin, growth factor, adipokine, RKS RACK and GW9662, and a pharmaceutically acceptable carrier.

44. The pharmaceutical composition according to item 43, where this isoform RKS selected from the group consisting of α, β, δ, ε, η and ζ.

45. The pharmaceutical composition according to item 44, where the specified growth factor selected from the group consisting of IL-6, KGF, and TNFα, as specified adipokine is adipsin or adiponectin.

46. The pharmaceutical composition according to item 43, where the specified substance is an inhibitor of the isoform of the RCC.

47. The pharmaceutical composition according to item 46, where the specified inhibitor isoforms RKS is an inhibitor α, preferably N-monitorowania peptide pseudoobscura α.

48. The pharmaceutical composition according to item 46, where the specified inhibitor isoforms RKS is an inhibitor η, preferably N-monitorowania peptide pseudoobscura η; or inhibitor ζ, before occhialino N-monitorowania peptide pseudoobscura ζ.

49. The pharmaceutical composition according to item 46, where the specified inhibitor isoforms RKS is an inhibitor α N-monitorowania peptide pseudoobscura α, and this additional tool is insulin.

50. The pharmaceutical composition according to item 43, where the specified substance is an activator isoforms RKS, preferably the activator δ, such as insulin or δ RACK.

51. Pharmaceutical composition for the induction of wound-healing process of epithelium, containing a therapeutically effective amount of a substance for inhibiting the expression or activation of at least one isoform of the RCC, adipokine and a pharmaceutically acceptable carrier.

52. The pharmaceutical composition according to § 51, where the specified adipokine is adipsin or adiponectin.

53. The pharmaceutical composition according to § 51, where this isoform RKS selected from the group consisting of α, β, δ, ε, η and ζ.

54. The pharmaceutical composition according to § 51, where the specified substance is an inhibitor α.

55. The pharmaceutical composition according to § 51, where the specified substance is an inhibitor η, preferably N-monitorowania peptide pseudoobscura η or inhibitor ζ, preferably N-monitorowania peptide pseudoobscura ζ.

56. Pharmaceutical compo is ice by § 51, where specified, a pharmaceutical composition includes a solid Foundation.

57. The pharmaceutical composition according to § 51, where specified pharmaceutically acceptable carrier designed for local use specified pharmaceutical compositions.

58. The pharmaceutical composition according to § 51, where the specified adipokine is adipsin.

59. The pharmaceutical composition according to § 51, where the specified adipokine represents adiponectin.

60. The pharmaceutical composition according to § 51, where the specified substance is N-monitorowania peptide pseudoobscura α.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to surgery, and can be used for post-surgical treatment of the patients after an intestinal obstruction surgery. That is ensured by the diversional therapy. It is added with the intravenous drop-by-drop introduction of ozonised physiologic saline of ozone concentration 5mg/l in amount 200 ml for the first seven postoperative days once a day.

EFFECT: reduced time of enteroparesis relief with higher physiological value of the treatment and extended range of products for enteroparesis relief in such patients.

2 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to surgery, and can be used for the early postoperative prevention of acute gastroduodenal ulcers in patients with colorectal cancer. That is ensured by the preoperative detection of Helicobacter pylori infection. Then for 5-7 preoperative days, amoxicillin in daily dose 2 g and clarithromycin in daily dose 1 g are administered orally.

EFFECT: method provides the prevention of acute gastroduodenal ulcers in the declared group of patients regardless the presence of pathological changes in the upper gastrointestinal mucosa.

5 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to urology, and can be used for treating complicated purulent pyelonephritis. That is ensured by the surgical intervention and starting from the early postoperative period, bleach solution is administered intravenously and locally. The intravenous introduction of 0.004% bleach solution is carried out once a day at 10 ml of the solution per 1 kg of body weight. Additionally, 0.06% bleach solution is introduced locally intrarenally with a nephrostomic drainage every 12 o'clock in amount 50 ml in divided portions no more than 4 ml for one portion. The therapeutic course is 7 days.

EFFECT: method provides reduced duration of staying in hospital, reduced postoperative complications of septic nature and reduced duration of healing of postoperative wounds in the patients.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to vascular surgery and can be used in treatment of patients with varicose disease of lower extremities. For this purpose into proximal end of vein introduced is intravascular catheter with its further movement in the same direction as vein trunks to saphenofemoral fistula under constant ultrasonic control of its movement. After that through catheter introduced is phlebosclerosant, as such solution of ozone on the basis of 0.9-2.0% solution of sodium chloride with ozone concentration 10-25 mg per 1 l of sodium chloride solution. Additionally sclerotherapy of varicose tributaries is carried out by puncture introduction of said solution.

EFFECT: method allows to simplify procedure considerably with simultaneous reduction of trauma due to elimination of carrying out crossectomy and eliminate thromboembolic complications due to effect of concentrated ozone solution on blood rheology.

3 cl, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to anesthesiology and surgery, and can be used in need of pain relief in post-operation period in patients subjected to laparotomy. For this purpose in formed on the right and on the left along all length of laparotomic wound, at 1.5-2.0 cm distance from its edges, tunnel installed are catheters which have several holes. Through installed catheters solution of local anesthetic is introduced into preperitoneal space every 3 hours during 3 days.

EFFECT: method allows to ensure adequate anesthesia in post-operation period due to possibility to create depot of local anesthetic in preperitoneal space.

2 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to surgery, and can be applied for patients with surgical sepsis. For this purpose subcutaneously introduced is sandostatin in dose 100 mkg 5 times per day and roncoleukin in dose 500 thousand IU 1 time per day. Introduction is realised for 2 days and 3 days after operation, as well as in 1 and 2 weeks of post operational period. Simultaneously on the same days during 1 hour hyperbaric oxygenation is carried out with partial pressure of oxygen 1.5-2 atmospheres.

EFFECT: method allows to reduce frequency of fatal outcomes in patients with said pathology due to immunomodelling action, which appears as a result of definite combination of pharmacological medications and hyperbaric oxygenation.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to antler deer farming. A haemostatic preparation after velvet antler cutting contains burnt potassium alum, anesthesin, microcellulose and camphor in the following ratio, wt %: burnt potassium alum 35-45; anesthesin 14-16; microcellulose 35-45; camphor 4-6. The preparation forms a protective layer with high absorbing, anaesthetising and repellent properties on a section surface.

EFFECT: invention provides effective haemostasis in a velvet antler cut-off and safety of the personnel in the use.

2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to surgery and gastroenterology, and can be used in treatment of patients with acute gastroduodenal hemorrhage. For this purpose fibrogasteroduodenoscopy is performed. Additionally through endoscope canal to source of hemorrhage brought is double-lumen Teflon catheter, through which during 5-7 minutes flow insufflation with ozone-oxygen mixture with concentration 90-100 mg/l and rate of gas flow 250 l/min, is carried out. Excessive waste gas mixture is removed to destructor.

EFFECT: method allows to increase efficiency and safety of endoscopic hemostasis due to ensuring local anti-hypoxia and systemic antioxidant effect with introduction of said mixture in definite mode.

4 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely, to surgery and intensive therapy, and can be used in treatment of patients with frostbites in pre-reactive and early reactive periods of trauma. For this purpose medications which as active component contain superoxiddismutase are used locally. After that heat-insulating bandage is applied for term not shorter than 24 hours.

EFFECT: method allows to ensure increased efficiency of local treatment of frostbites due to pathogenetic impact aimed at stopping effects of oxidative stress and tissue hypoxia resulting from combined effect of medication, in which superoxiddismutase is used as active substance, and heat-insulating bandage.

1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to surgery and intensive therapy, and can be used in treating endotoxicoses caused by septic conditions. That is ensured by removal of a destruction area to be thereafter sanitised and drained. It is followed with lymphostimulating therapy by introduction of 0.25% Novocaine 60 ml with dissolved 0.1 g of Lydase and 1.0 ml of Pentoxifylline into the interspinous spaces in number of 1-3 injections. Further, discrete plasmapheresis in amount 400 ml for severe patients and 800 ml in moderate patients is applied in number of 1-8 procedures. The lymphostimulating therapy is alternated every second day with lymphotropic extracorporal pharmacoimmunotherapy with using a medicated mixture prepared by incubation of 40-60 ml of the patient's plasma with received plasma of the patient with Roncoleukin in dosage 500-1 million UN and Cefabol in dosage 1 g for 45 min at 37°C. In peritonitis and peritoneal sepsis, the medicated mixture is introduced in the bolus form in the retroperitoneal fat. The destructive processes in the pleural cavity require introduction of said mixture in the axillary cavity.

EFFECT: method provides endotoxin weakening in the bloodstream, intertissue spaces and cavities due to combined multidirectional local and system effect on the lymphoid system.

3 cl, 8 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to hydrophilic pharmaceutical compositions for treatment of burn wounds. According to the first version of invention, pharmaceutical composition contains 1-β-oxyethyl)-4,6-dimethyl-1,2-dihydro-2-oxopyrimidine (xymedone) in amount of 1-10 wt %, chloramphenicol sodium succinate in amount of 0.1-5 wt % and gel base. According to the second version of invention, pharmaceutical composition contains xymedone in amount of 1-10 wt %, chloramphenicol sodium succinate in amount of 0.1-5 wt %, tri-(oxymethyl)-aminomethane (trisamine) in amount of 0.5-1.5 wt %, anesthesin in amount of 0-1 wt % and gel base.

EFFECT: compositions of invention are efficient for treatment of infected burn wounds, possess reparative, anti-inflammatory and antimicrobial effect as a result of synergetic and prolonged effect of xymedone and chloramphenicol sodium succinate.

8 cl, 2 tbl, 10 ex

FIELD: medicine.

SUBSTANCE: invention relates to the field of medicine, in particular to dentistry, and represents antiseptic pharmaceutical paste-like composition for application onto mucous membrane of mouth cavity containing efficient amount of 5-nitroimidazole derivative and paste-like base, consisting of at least 18% of overall mass of composition of adhesive components, representing polysaccharides or their derivatives, collagen or its derivative, copolymers of methacrylic acid, resins, derivatives of resins, gelatin, polyvinylpyrrolidone or mixture of specified substances and at least 25% of overall mass of composition of fat filler representing paraffin hydrocarbon or ester of higher fatty acids and higher alcohol or mixture of specified substances.

EFFECT: invention provides for production of mass having consistence of stable paste, which is capable of adhesion and retention on surface of parodentium for at least 10 minutes, providing for durable admission of antibacterial substance in zone of inflammation, reduction of edema and inflammation of parodentium.

16 cl, 3 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to dermatovenerology and gynaecology and to treatment of anogenital warts. For this purpose 30% glicifon ointment is applied onto lesion foci. Ointment is applied daisy in a thin layer for 6-8 hours. Course of treatment is 5-14 days.

EFFECT: method provides for efficient destruction of warts without systematic side effects.

3 ex

FIELD: medicine, veterinary science.

SUBSTANCE: invention refers to veterinary science. The method involves the application of ointment on a wound surface every 24 hours to complete healing. The ointment contains silica marl and polyethylene oxide - 1500 and 400 taken in the ratio 1:1,5 respectively.

EFFECT: method allows to reduce healing time of the wound defects and to ensure higher clinical effectiveness in septic skin and muscular wounds in animals.

1 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of pharmaceutics and deals with multivitamin ointment for skin softening, nutrition and healing, which contains fat-soluble vitamins A, E, D3, antioxidants, emulsion wax, vaseline oil, glycerol, ethyl alcohol and water, and method of obtaining it.

EFFECT: there is claimed multivitamin ointment for skin softening, nutrition and healing.

3 cl, 2 dwg, 2 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine and pharmacology, namely to compositions for infected wounds treatment. Application of ointment: for treatment of post-operational wounds, as well as old, abundantly seeded with pathogenic microflora wounds, difficult or impossible to heal, turning trophic. Ointment based on gel based on various polyethylene oxides (PEO-400, 1500, 2000, 4000) contains active substances: stabilised zol of silver nanoparticles and proteolytic means - chymopsin, trypsin, chymotrypsin.

EFFECT: invention adds to ointment prolonged synergetic medicinal and antiseptic effect.

8 ex, 1 tbl

Wound healing agent // 2396972

FIELD: medicine.

SUBSTANCE: invention refers to chemical-pharmaceutical industry, namely to creation of a wound healing agent. The wound healing agent contains a dry extract of Sphagnum fuscum peat dust, polyethylene glycol of molecular weights 400 and 1500, Dimexid, purified water.

EFFECT: agents extends the range of herbal wound healing products, exhibits wound healing action for treating infected wounds.

1 tbl

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science. The method involves coating of empty udder skin with a thin layer of an ointment. The ointment contains Dimexid in amount - 1%, Vaseline - 85-95%, staphylococcal anatoxin - the rest.

EFFECT: use of the method improves clinical effectiveness, accelerates the recovery time.

2 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, specifically to a composition for treating dermatoses. The pharmaceutical composition for treating skin affections contains mometazone furoat as an active ingredient, and a hydrophobic phase, a hydrophilic phase, a mat additive, macrogol cetostearate, glyceryl monostearate and cetostearyl alcohol as adjuvants. The hydrophobic phase represents vaseline and white wax. The hydrophilic phase represents hexylene glycol, phosphoric acid and water. The mat additive represents aluminium starch octenylsuccinate and titanium dioxide. The pharmaceutical composition is presented in soft dosage form, preferentially as cream. The method for preparing the composition involves slurrying of the mat additive in fused vaseline, addition of glyceryl monostearate, cetostearyl alcohol, macrogol cetostearate and white wax to suspension, and emulsification in the prepared mixture of mometazone furoate solution in the hydrophilic phase.

EFFECT: new composition is characterised by high pharmacological activity, storage-stability, good packing extrusion, high degree of uniformity and optimum pH.

8 cl, 1 tbl

FIELD: medicine.

SUBSTANCE: as active substances containing propolis extract, complex of carbon dioxide extracts of arnica, birch, green tea, nettle, chamomile, complex of carbon dioxide extracts of garlic and melissa, buck-eye, medical bile, camphor, mummy, dimethylsulphoxide, athyl alcohol, carbomer, triethanolamine, euxyl, essential oil of juniper; in addition, preparation contains capsinum, essential oil of mint, menthol, extract of pepper, carbon dioxide extract of Siberian fir, complex of carbon dioxide extracts of sea-buckthorn, parsley, licorice.

EFFECT: claimed external preparation produces complex effect in zone of application, is convenient and efficient in any situation, when quick correction of recipient's state is necessary in case of absence of qualified medical or veterinary aid.

3 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: method of obtaining dry diketopiperaxine powder includes obtaining diketopiperazine solution, stage of diketopiperazine-containing particles formation and removal of solvent by drying by means of dispersion. Method can include additional stage of loading diketopiperazine particles with active agent, which represents peptide or protein, preferably, insulin. Diketopiperazine preferably is fumaryldiketopiperazine. Diketopiperazine particles, obtained by invention method, possess improved aerodynamic characteristics, active agent, in particular insulin, is more stable and is delivered in more efficient way in comparison with composition of diketopiperazine-insulin, dried by means of sublimation.

EFFECT: dry powders are used as compositions of pharmaceutical preparations for delivery in pulmonary way.

16 cl, 10 dwg, 5 tbl, 8 ex

Up!